PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.09%
R&D reduction while TRVN shows 65.23% growth. Joel Greenblatt would examine competitive risk.
3.56%
G&A growth less than half of TRVN's 14.43%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency.
-26.91%
Operating expenses reduction while TRVN shows 51.78% growth. Joel Greenblatt would examine advantage.
-26.91%
Total costs reduction while TRVN shows 51.78% growth. Joel Greenblatt would examine advantage.
10.26%
Interest expense growth less than half of TRVN's 54.02%. David Dodd would verify sustainability.
-96.48%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-115.63%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
27.06%
Operating income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-198.08%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-304.05%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
113.79%
Tax expense growth above 1.5x TRVN's 54.28%. Michael Burry would check for concerning trends.
-304.05%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-302.06%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-288.66%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.11%
Share count change of 0.11% while TRVN is stable. Bruce Berkowitz would verify approach.
3.68%
Diluted share change of 3.68% while TRVN is stable. Bruce Berkowitz would verify approach.